Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors - Concepedia

Concepedia

Publication | Open Access

Identifying a Clinically Applicable Mutational Burden Threshold as a Potential Biomarker of Response to Immune Checkpoint Therapy in Solid Tumors

DOI Full Paper Access

66

Citations

33

References

2017

Year

Anshuman Panda, Anil Malleshi Betigeri, Kalyanasundaram Subramanian, Jeffrey S. Ross, Dean C. Pavlick, Siraj M. Ali, Paul Markowski, Ann W. Silk, Howard L. Kaufman, Edmund C. Lattime,

JCO Precision Oncology

Abstract

In 8 solid cancers, a mutational burden threshold exists that may predict response to immune checkpoint blockade. This threshold is identifiable using available clinical sequencing assays.

References

	Year	Citations

Page 1